Martine A. Rothblatt, serving as both Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ:UTHR), disclosed a series of share transactions on July 22, 2026. The filings indicate the sale of common stock valued at approximately $5.04 million. These sales were part of a structured, pre-arranged trading mechanism. On the identical date, Rothblatt also utilized stock options to acquire additional equity in the company.
The executive disposed of 8,600 shares of United Therapeutics common stock. The sales occurred within a price range of $524.15 to $539.71 per share. The weighted average price for these transactions fell between $524.27 and $539.47, resulting in a total transaction value of $5,040,379. United Therapeutics shares currently trade at $529.70. This valuation reflects a 72% increase over the past twelve months, indicating sustained investor interest in the biotechnology firm, which holds a market capitalization of $22.4 billion.
Simultaneously, Rothblatt acquired 9,500 shares of common stock by exercising stock options. The exercise price was set at $135.42 per share, leading to a total acquisition cost of $1,286,489. Both the option exercises and the subsequent share sales were governed by a Rule 10b5-1 trading plan. This plan was established by Rothblatt on November 7, 2025. It remains active until the earlier of two conditions: the exercise of 1,734,410 stock options, all of which are set to expire on March 15, 2027, or December 31, 2026.
Following these transactions, Rothblatt's beneficial ownership of United Therapeutics common stock stands at 748,828 shares. This total comprises 40,513 shares held directly. Indirect holdings include 324,443 shares through a family trust where she shares investment power. Additional indirect holdings consist of 166 shares held by her spouse, 249,108 shares in family trusts where her spouse serves as a trustee, and 45,596 shares in family trusts with shared investment power. Furthermore, she holds 89,002 shares in family trusts where she acts as a trustee. She also indirectly holds 293,910 stock options through a family trust.
Financial health assessments from InvestingPro assign United Therapeutics a "GREAT" score, supported by an 87% gross profit margin. However, fair value analysis from the same source places the stock on a list of overvalued companies. Investors may access UTHR's comprehensive Pro Research Report on InvestingPro for deeper insights.
In recent corporate developments, the U.S. Food and Drug Administration granted premarket approval for United Therapeutics' LungFX lung perfusion device. This device facilitates the centralized evaluation of donor lungs outside the body, aiming to enhance the transplantation process. Additionally, TD Cowen reiterated a Buy rating for United Therapeutics, setting a price target of $675.00. This action followed discussions with a leading pulmonologist involved in the TETON studies.
Broader market context includes BETA Technologies completing the first electric aircraft flights under the FAA's eVTOL Integration Pilot Program. These flights, conducted with state aviation departments, covered approximately 275 nautical miles across Virginia and Maryland. In the biopharmaceutical sector, Raymond James expressed optimism regarding Insmed's upcoming earnings, suggesting potential for results to exceed 2026 consensus expectations.